From now on, Fuzhou can receive domestic bivalent cervical cancer vaccine

Shanghai Subdistrict Health Service Center in Taijiang District, Fuzhou City can accept domestic bivalent cervical cancer vaccination (photographed by Feng Chuanye, reporter of Southeast Network)

Difference tips of several cervical cancer vaccines posted by Community Health Service Center (Reporter Feng Chuan of Southeast Network) Photo by Ye)

Taihai.com, September 17 news. According to the report from Southeast.com, the reporter learned from the Shanghai Street Health Service Center in Taijiang District, Fuzhou City that the domestic bivalent cervical cancer vaccine has already arrived at the center, and citizens can go to the site for vaccination. The reporter from

saw on the spot that the domestic bivalent cervical cancer vaccine has attracted much attention, and now some people come to consult the domestic bivalent cervical cancer vaccine. The staff of the center told reporters that the cervical cancer vaccine is currently in sufficient supply, and citizens can go directly to the site for vaccination without making an appointment. The Health Service Center reminded that HPV screening should be performed before the cervical cancer vaccine. The

domestic bivalent HPV vaccine was jointly developed by Xiamen Wantai and Xiamen University and transformed by Wantai. It is the first HPV vaccine independently developed in my country. The price of this domestic cervical cancer vaccine is 329 yuan/injection, plus the vaccination service fee is 30 yuan/injection. It is suitable for women between 9 and 45 years old, including two injections for 9-14 years old and three injections for 15-45 years old. As cervical cancer is the only malignant tumor with a clear cause, preventable and curable, vaccination is an effective primary prevention method. The first domestic bivalent cervical cancer vaccine was vaccinated in Xiamen recently. Before the domestic cervical cancer vaccine was approved, there were imported bivalent, quadrivalent and ninth-valent HPV vaccines on the domestic market, which were suitable for women aged 9-45, 20-45 and 16-26. Compared with other cervical cancer vaccines, the domestic bivalent cervical cancer vaccine has a great advantage in price. (Reporter Feng Chuanye)